From Policy to Implementation: The Next Challenge for Drug Pricing and Market Access

As drug pricing policies continue to evolve, manufacturers face a growing challenge: translating regulatory requirements into practical decisions about pricing, reimbursement, data, and market access.

The pace of change in US drug pricing policy shows little sign of slowing. From Most Favored Nation (MFN) pricing and 340B reform to Medicare reimbursement and implementation of the Inflation Reduction Act (IRA), manufacturers are navigating an increasingly complex and interconnected environment.

Yet understanding the policies themselves is only part of the challenge. How these changes are implemented, and how they affect manufacturers, providers, and patients, may prove just as consequential.

Following the 2026 Medicaid Drug Rebate Program Summit, Amanda Forys, Managing Partner at Magnolia Market Access, joined Chris Schott, Partner at Latham & Watkins, and Sabrina Aery, Founder of Aery Policy & Access Partners, on the Connected With Latham podcast. Their discussion explored key drug pricing developments and the challenges manufacturers face as these policies move toward implementation.

The conversation highlighted an important consideration for market access leaders: regulatory developments must be evaluated not only for their intended outcomes but also for the operational and financial challenges they may create.

Tree icon surrounded by circle graph

The Gap Between Policy Design and Practical Implementation

One of the most significant developments discussed at the conference was the finalization of the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, which introduces an international reference pricing approach into Medicare Part B.

Amanda observed that much of the conference discussion centered on how substantially the final model differed from its original proposal. With fewer manufacturers and drugs included, the anticipated financial impact was considerably smaller than initially projected.

That raises a broader question about the relationship between policy objectives and the complexity of implementation. Even when a model’s scope narrows, manufacturers must still assess whether they are affected, understand the applicable requirements, and evaluate the potential implications for their businesses.

A similar challenge is emerging with changes to the 340B Drug Pricing Program. While policy discussions have focused on improving oversight, addressing duplicate discounts, and increasing transparency, implementation introduces practical questions about data exchange, administrative responsibilities, and financial implications for participating organizations.

For manufacturers, anticipating these challenges is becoming an increasingly important part of market access planning.

Tree icon surrounded by circle graph

340B Implementation Will Depend on Data Accuracy and Operational Readiness

The evolving 340B rebate model illustrates how a policy intended to improve program integrity can introduce new operational considerations.

Under the rebate approach discussed in the podcast, participating covered entities would receive rebates after purchasing eligible drugs rather than receiving the discounted price upfront.

Amanda emphasized the importance of understanding how the model will function in practice, particularly the exchange of information between manufacturers and covered entities.

Perspectives on the administrative burden differ. Some stakeholders believe existing 340B data infrastructure can support the transition without substantial additional work. Others anticipate significant challenges in implementing the new processes. These differences point to the importance of assessing actual operational capabilities rather than assuming a consistent experience across organizations.

Data accuracy is particularly important. Manufacturers need reliable information to identify eligible claims, validate rebate requests, and avoid providing duplicate discounts.

Claims identification remains a challenge, especially when information moves across medical and pharmacy benefit channels. During the podcast, Amanda discussed the limitations of current claims modifiers and the need for more sophisticated auditing to support accurate rebate administration.

The need for stronger auditing extends beyond collecting additional information. Manufacturers must also be able to evaluate the completeness and accuracy of submissions and determine whether existing processes provide adequate visibility into rebates and discounts.

The discussion also raised questions about the enforceability of data reporting through potential clearinghouse approaches. Even where centralized systems could improve transparency, their effectiveness would depend on the consistency and reliability of the information submitted.

As more pricing requirements overlap, accurate claims identification, effective data exchange, and appropriate auditing processes will become increasingly important to program administration.

Tree icon surrounded by circle graph

Reimbursement Changes May Affect Covered Entities Differently

Operational readiness is only one consideration. Changes to drug pricing and reimbursement can also have different financial implications depending on the organizations involved.

Amanda highlighted the potential impact of the 340B rebate model on smaller covered entities, including rural facilities, clinics, and federally qualified health centers.

Unlike larger health systems, these organizations may have fewer financial resources to manage the transition from upfront discounts to retrospective rebates. Even when rebates are paid within established time frames, changes in cash flow could create challenges for providers with limited financial flexibility.

These concerns also extend to proposed Medicare Part B reimbursement reductions for 340B drugs.

During the discussion, Amanda questioned whether the potential impact of reimbursement reductions has been sufficiently studied, particularly in light of previous periods when Medicare payments for 340B drugs were reduced. Understanding what actually occurred during those periods could provide valuable evidence for evaluating future payment policies.

Rather than assuming that all covered entities will experience comparable financial effects, policymakers may need to consider differences in provider size, geography, ownership, and financial resources.

Amanda raised the possibility of alternative payment mechanisms or targeted support for organizations that could experience disproportionate financial effects. These could include additional safety-net payments or different reimbursement approaches for certain provider categories.

These considerations highlight a broader market access issue: changes to drug reimbursement cannot be evaluated solely through the lens of manufacturer pricing or federal program spending. Provider economics and financial sustainability may also influence how policies affect healthcare delivery and patient access.

Tree icon surrounded by circle graph

Connecting Policy Developments to Market Access Strategy

The challenges discussed extend beyond 340B.

Changes to Average Sales Price (ASP) reporting, including requirements surrounding bona fide service fees, create additional considerations for manufacturers’ contracting and reporting processes.

Meanwhile, continued implementation of the IRA is influencing how companies evaluate product development and commercialization decisions.

Amanda noted that manufacturers are already considering questions about indication sequencing, packaging, and formulation as they evaluate the implications of Medicare drug price negotiation.

These considerations illustrate how policy developments can become part of product strategy well before a particular pricing requirement takes effect.

The extension of negotiated Maximum Fair Prices into Medicare Part B also raises questions about reimbursement processes and financial exposure for providers operating under the buy-and-bill model.

Although the specific implications vary by product and manufacturer, these developments reinforce the importance of evaluating pricing policy as part of a broader market access strategy.

For manufacturers, several considerations deserve attention:

  • Portfolio exposure: Understanding which products and business activities may be affected by current and proposed policy changes.
  • Data and operational readiness: Evaluating whether existing reporting, claims validation, and auditing capabilities can support evolving requirements.
  • Provider and channel implications: Assessing how reimbursement changes may affect covered entities, provider economics, and distribution channels.
  • Cross-functional coordination: Connecting policy intelligence with pricing, contracting, finance, analytics, and commercialization planning.

The challenge is not simply identifying each new policy development. It is understanding how those developments intersect and determining which actions warrant attention.

Tree icon surrounded by circle graph

Looking Ahead

The evolving drug pricing environment presents manufacturers with a complex set of decisions, many of which extend beyond traditional policy and compliance functions.

As new requirements take effect and additional models are considered, manufacturers will need to assess how regulatory developments translate into operational requirements, financial implications, and potential effects on market access.

That requires more than monitoring policy announcements. It calls for an integrated approach that considers the relationships among pricing, reimbursement, data, provider economics, and long-term product strategy.

For biopharma manufacturers, understanding these connections will be essential to navigating continued change and making informed market access decisions.

Tree icon surrounded by circle graph

Continue the conversation

Magnolia Market Access helps biopharma organizations evaluate the implications of evolving health policy and translate complex market dynamics into informed market access strategies.

Listen to the full podcast

Hear Amanda Forys, Chris Schott, and Sabrina Aery discuss their takeaways from the 2026 Medicaid Drug Rebate Program Summit on Latham & Watkins’ Connected With Latham podcast: Drug Pricing and Market Access: Takeaways from the Medicaid Drug Rebate Program Summit 2026.